Posts tagged ADT
Prostate cancer study shows benefit of 3DS’ telomere signature analysis

Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures’ (OTCQB:TDSGF; TSX-V:DXD) technology platform, TeloView, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT).

Read More
WB starts Collegium Pharma at outperform

William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday.

Collegium’s lead product, Xtampza ER, an extended-release oxycodone-based product with abuse-deterrent technology (ADT), has received tentative approval from the FDA for the treatment of chronic pain that requires around-the-clock opioid analgesia for an extended period.

Read More